The most telling discrepancy: Death appears MORE frequently than hyperthermia yet hyperthermia is listed on the label while death is not.
Elanco claims: Basic functions like eating, drinking, and elimination are unaffected.
Reality: “Not eating” and “Not drinking” rank among the most common adverse events.
How can veterinarians provide informed consent when the manufacturer’s claims directly contradict documented outcomes?
Data sources: Elanco veterinary materials (archived November 2025); FDA Adverse Event Reporting System
Elanco’s recent marketing materials for Zorbium® feature images of both dogs and cats, despite the fact that Zorbium® is FDA-approved for cats only. This visual presentation creates dangerous confusion in the veterinary community.
What We Found
Document: Multimodal Analgesia Technical Bulletin
Source: Elanco official website, Zorbium® product pages
Content: Educational material featuring both dog and cat imagery
Problem: Implies the medication is appropriate for both species
Why This Matters
FDA Approval Status:
- ✅ Cats: Post-surgical pain management only
- ❌ Dogs: Not approved for any use
- ❌ Other species: Not approved for any use
The Dangerous Implication: When veterinarians see marketing materials showing dogs alongside a pain medication, the natural assumption is that the drug is safe and approved for canine use.
Real-World Consequences
This type of mixed-species marketing contributes to the off-label use crisis we’ve been documenting:
- Veterinarians assume “if there’s a dog in the picture, it must be okay for dogs”
- Creates false equivalency between species
- Leads to dangerous dosing assumptions
The Buprenorphine Confusion
Many veterinarians already confuse Zorbium® with traditional buprenorphine products:
- Traditional buprenorphine: Used off-label in multiple species
- Zorbium®: Specifically formulated and tested for cats only
- Key difference: Transdermal delivery system with 4-day duration
Marketing materials showing dogs exacerbate this dangerous misconception.
Documentation
We maintain copies of these marketing materials as evidence of how misleading visual presentation contributes to off-label misuse.
The bottom line: Marketing materials should match FDA approval status. Dog imagery on cat-only medications creates preventable confusion that puts animals at risk.
Last updated: June 2025
“Not Tested on Kittens” — The Label Loophole
What The Label Says:
“The safe use of ZORBIUM® has not been evaluated in cats younger than four months old”
What This Makes You Think:
Zorbium® wasn’t tested on kittens, so the drug is intended only for adult cats.
What The Studies Actually Show:
- Both Phase 2 and Phase 3 approval studies included 4-month-old cats
- Mean age in studies: 10.3 months (still within kitten developmental stage)
- Kittens are defined as birth to 12 months by veterinary standards
Why This Matters:
- 4-month-old cats ARE kittens with immature organ systems
- Kittens metabolize drugs differently than adult cats
- The label creates false security about age-appropriate use
- Veterinarians may assume “4 months and up” means fully developed cats
The Deception:
By stating “not evaluated in cats younger than four months,” the label:
- Sounds protective and cautious
- Implies kittens were excluded from testing
- Obscures the fact that the youngest test subjects WERE kittens
- Creates a misleading impression of the tested population
Clinical Implications:
- Veterinarians may not realize study cats were still in developmental stages
- No safety data exists for cats under 4 months (true kittens)
- The 4-month cutoff appears arbitrary given kitten physiology extends to 12 months
- FDA reports include deaths in young cats
Sources: FDA Phase 2 Clinical Study (Clark et al., 2022), FDA Phase 3 Clinical Study (Clark et al., 2022), FDA Freedom of Information Act Response (Study NCY05-L-18)